Veterinary drugs based on a set of bacteriophages.

Veterinary drugs development for the treatment of infectious diseases including antibiotic-resistant drugs.

Photo of Nikita
0 0

Written by

I confirm that I am fully aware of the eligibility criteria and terms of the Purina BetterwithPets Prize and, based on its description, I am eligible to apply:

  • Yes, I’m eligible
  • Yes, I’m 18 years old or older

Should you be successful, please confirm your availability to attend:

  • Additional Skype interview(s) during the week of March 16-20th 2020
  • The Purina BetterwithPets Forum in Paris, on 3-4th of June 2020

Initiative's representative name

Nikita Borisov

Initiative's representative date of birth

6081986

Initiative's representative gender

  • Man

Headquarters location: country

  • Russia

Headquarters location: city

Moscow

Where are you making a difference?

In the future these are countries where the usage of antibiotics in veterinary medicine is regulated at the state level (Russia, Great Britain and other countries).

Website or social media url(s)

https://sk.ru/net/1122928/

Date Started

11/2019

Focus Areas

  • Revolutionizing veterinary care for pets

What is your current yearly budget for the initiative? If you are an idea stage, what early budget you would need to kick-off and run operations in your first year?

  • €1k - €10k

Organisation Type

  • hybrid: a combination of different types of organisations, such as a social enterprise (an organisation that applies commercial strategies to maximize improvements in human and environmental well-being)

1. Founding story: Share a story about the "Aha!" moment that led the founder(s) to get started or the story of how you saw the potential for this project to succeed.

A team of like-minded people was formed in 2018 in order to search for an alternative method of infectious diseases of bacterial origin in veterinary medicine prevention and treatment. The need to create an innovative drug was caused by the problem of a comprehensive solution of prevention and treatment of animals in increasing antibiotic-resistant of microorganisms conditions.

2. The problem: What problem are you helping to solve?

Problems that will be solved: - the growth of antibiotic-resistance of microorganisms, decrease of superinfection level - decrease of pets deaths, economic harm in agriculture and fish farming; - state regulation of antibiotics use in veterinary; - search and use of safe and effective alternative antibacterial agents of natural origin in veterinary and production (food safety).

3. Your solution: How are you planning to solve this problem? Share your specific approach.

The basis of the project is creation of composition, technologies and drug usage methods based on bacteriophages for the treatment and prevention of animals infectious diseases. Intellectual property protection/ Further drug registration in a different countries. Drug creation will help to prevent the occurence and spread of the resistance of microorganisms to antibiotics as a result of a decrease of their use. There will be developed and registered drugs for treatment of major infectious diseases. An optimal cocktail of bacteriophages will be selected for each drug in order to resist such pathogens as salmonella, streptococcoccus, staphylococcus, Escherichia coli, clostridia and others. It is planned to create a collection of virulent bacteriophages and host bacteria and their update on a regular basis. In addition work on creation of map of sensitivity to collectible bacteriophages will be held.

4. Innovation: How are you innovating or using unique approaches to solve the problem?

The development and implementation of bacteriophage drugs for the treatment and prevention of infectious diseases caused by pathogenic microflora which is resistant to various types of antibiotics can be an effective replacement for a current global trends in the infections treatment in veterinary. Currently there are no registered and approved bacteriophage drugs for use in veterinary. Furthermore, the innovativeness of the approach consists in the allocation and creation of universal bacteriophages that are specific for the same type bacteria as well as studying of the genome of a bacterial cell in order to overcome resistance occurrence of phages of the same type bacteria.

5. How does your project harness the pet-human bond to help people develop important social competencies (For example: emotional intelligence, collaboration, empathy, resilience, inclusivity) and overcome serious societal issues (for example: violence, abuse, trauma, isolation, abandonment)?

The resistance of bacterial infections against antibiotics has a negative effect on the global healthcare system. If effective measures are not taken, then the near future will become similar to the Apocalypse: more people will die due to drug resistance than currently dying because of cancer and diabetes combined. The problem of bacterial resistance against antibiotics covers several areas of life at once. First of all, of course, it is healthcare and the economics. According to Rewiew on Antimicrobial Resistance large-scale research commissioned by the British government, the future looks very frightening. The global annual mortality due to antibiotic resistance will reach more than 10 million by 2050 which is totally more than the deaths due to cancer diseases and diabetes currently (8.2 million and 1.5 million respectively). Expenses will reach a huge amount: up to 3.5% of the total GDP or up to $ 100 trillion.

6. Impact: how has your project made a difference so far in terms of both business outputs and social impact? How do you plan on measuring progress?

To date, the team has become a resident of Skolkovo Innovation Fund and it is planned to start an active research and development with expanding the team to 7-9 people and attracting investments. Project development is supported by the availability of sites and equipment for research maintenance.

7. Growth strategies: what are your main strategies for scaling your impact?

Stage 1 (2020-2022): creation of working experimental models, testing of characteristics, features, parameters, registration of test results; obtainment of a registration certificate and a product patent, production of an experimental batch; project profile co-investor attraction. Stage 2 (2022-2024): pilot production launch, creation of a pilot area on the basis of a modular research pilot line - creation of a pilot industrial sample; modular research pilot line launch; preparation of the product for mass production; formation of own trademark; maintenance of sales of an innovative product.

8. Creating shared value: How does your initiative create value for different stakeholders?

New means of battle against bacteria are needed as never before - ordinary people and animals primarily suffer of the current situation. Antibiotic resistance affects the incidence, mortality and cost of patients treatment. This process can affect anyone: cost of treatment and time spent in the hospital increase, the risks of complications and death constantly grow. The British estimate global annual mortality of at least 700 thousand people. In the United States alone, the Centers for Disease Control and Prevention (CDC) estimates that more than 2 million people are affected by antibiotic-resistant infections each year. In addition to the obvious problems with population health, for the state this means additional budget costs.

9. Financial sustainability plan: can you tell us about your plan to fund your project and how that plan will be sustainable in the short, medium, and long term?

LifePhage company was founded in November 2019. To date, financing is planned through the receipt of grant funds and by attracting investors in the further step. The main focus will be done on the European and Russian market, where the usage of antibiotics in veterinary is being regulated.

10. Team: what is the current composition of your team (types of roles, qualifications, full-time vs. part-time, board members, etc.), and how do you plan to evolve the team’s composition as the project grows?

Borisov Nikita - project leader, veterinarian, project coordination, interaction with scientific groups, regulatory organizations. Development and medical and economic proof of optimal proposals for the integrated development of the project. Vasiliev Dmitry - Professor, Head of the Department of Microbiology, Virology, Epizootology and Veterinary Sanitary Expertise at Ulyanovsk State Agrarian University, coordination of work and research work, Hirsch Index - 34. And other participants.

11. How do you plan to influence your field of work if you are a winner of this edition of the Purina BetterwithPets Prize?

We plan to create and implement the sustainable use of safe and effective products based on bacteriophages in veterinary. To do this, a large amount of work remains to be done and all participants are ready to do this work with joy since each of us understands that this is a contribution to the mankind future.

12. How did you hear about this challenge?

  • Recommended by others

0 comments

Join the conversation:

Comment